Stifel Starts Iveric Bio (ISEE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Wall St set for best week since April as payrolls surprise eases rate-hike jitters
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on US jobs report, worries over peace talks
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Iveric bio (ISEE): APLS Data As Good As Possible for Iveric, Buy Here - Analyst
September 10, 2021 8:30 AM EDTLate Thursday, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
OAKS study met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively, compared to pooled sham at 12 months
DERBY did not meet the primary endpoint of GA lesion growth,... More
Iveric Bio (ISEE) PT Raised to $21 at Wedbush
September 10, 2021 7:41 AM EDTWedbush analyst David Nierengarten raised the price target on Iveric Bio (NASDAQ: ISEE) to $21.00 (from $16.00) while maintaining an Outperform rating.
"In our opinion the Phase 3 results announced by APLS (Neutral, Laura Chico) represent a best-case scenario for ISEE shares," the analyst commented.
... MoreIveric Bio (ISEE) PT Raised to $25 at Cowen; APLS Data Disclosure 'As Good As Possible for Iveric'
September 10, 2021 6:48 AM EDTCowen analyst Ken Cacciatore raised the price target on Iveric Bio (NASDAQ: ISEE) to $25.00 (from $15.00) while maintaining an Outperform rating, saying the data from competitor APLS is as good as possible for the company.
The analyst commented, "The APLS results could not... More
After-Hours Stock Movers 09/09: (ISEE) (AFRM) (KPLT) Higher; (APLS) (COOK) (ZUMZ) Lower (more...)
September 9, 2021 5:52 PM EDTAfter-Hours Stock Movers:
IVERIC bio (NASDAQ: ISEE) 41.4% HIGHER; gains following data from Apellis
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) 30.8% LOWER; reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OAKS met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan, demonstrating a significant reduction in GA lesion growth of 22% (p=0.0003) and 16% (p=0.0052), respectively,... More
UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)
September 9, 2021 4:14 PM EDT(Updated - September 9, 2021 4:22 PM EDT)
IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)
Shares Up 17%Update:
Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More